Evonik Qualifies Filling Line for Parenteral Drug Products at its Alabama Facility

Article

The new line has the ability to aseptically fill powder, liquid, suspension, and combination forms into vials in clinical or commercial batch sizes.

Evonik, a contract development and manufacturing organization (CDMO) focused on drug delivery, announced on Sept. 9, 2020 that it has qualified its advanced aseptic filling line, VarioSys, for complex parenteral drug products at its Birmingham, AL, facility.

The new line has the ability to aseptically fill powder, liquid, suspension, and combination forms into vials in clinical or commercial batch sizes, a company press release said. The VarioSys line also features automated weight verification and interchangeable components and equipment to maintain the high-yield manufacturing of intricate filling processes.

The filling line can work in conjunction with highly potent, personalized or sensitive drug products and specialized vaccines formulated for systemic or localized delivery of small molecules, peptides, proteins, and nucleic acids, the press release said.

“The ability to cost-effectively fill complex parenteral drug products in powder and other forms within an aseptic environment has been a major unmet need for pharmaceutical companies,” said Paul Spencer, head of Pharma Polymers and Services at Evonik’s Health Care business line, in the press release. “The qualification of this advanced, modular filling line at our Birmingham facility will further enhance our ability to serve as a preferred partner to pharmaceutical customers during the formulation development and cGMP manufacturing of their polymeric and lipid-based parenteral drug products.”

Source: Evonik

Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content